Latest Headlines

Latest Headlines

Japan's Astellas adds to U.S. ops with regenerative biotech acquisition

Japan's Astellas Pharma said it is paying $379 million in case to buy Ocata Therapeutics, a biotechnology cmpany that specializes in regenerative drugs to treat macular degeneration, according to a report by the  Boston Globe.

Pfizer, Allergan eyeing Saunders for CEO spot if a deal goes through: Bloomberg

Pfizer and Allergan are currently in "friendly" merger talks. And if they do tie the knot, it's looking like Allergan CEO Brent Saunders will take the helm.

Boston Sci moves deeper into oncology with $70M+ purchase from CeloNova

Cardiovascular-focused Boston Scientific is moving deeper into oncology and expanding its vascular offerings with the purchase of the interventional radiology portfolio of CeloNova BioSciences. The deal with the San Antonio, TX-based startup involves a $70 million upfront payment with additional, undisclosed regulatory and sales milestones.

Astellas offers $379M buyout for a pioneering stem cell survivor

Astellas Pharma has stepped up with a $379 million bid for Ocata Therapeutics, a pioneering--and often controversial--stem cell company that has managed to survive a years-long roller coaster ride through the hype, hope and disappointments of the past decade.

How badly does Pfizer need a tax inversion? Depends how you parse the numbers

How big is Pfizer's "tremendous disadvantage" from its U.S. tax rate? Bigger when you report your foreign earnings the way the pharma giant does. Pfizer told shareholders it had a 25.5% global tax rate in 2014, but had it reported its foreign earnings the way most U.S. companies do, that figure could have dropped to 7.5%, The Wall Street Journal reports.

FT: Amgen in the hunt for a $10B biotech buyout

Amgen is jumping back into the M&A game. And it's looking for another Onyx-sized deal that can deliver a late-stage drug ready to be hustled across the finish line.

Ex-trailblazer Knome accepts buyout bid from tiny Tute

Tute Genomics has acquired Knome for an undisclosed fee. The deal brings to an end Knome's 8-year, $20 million attempt to find a place for itself in the emerging genomics industry, during which time it sequenced the DNA of the super rich, branched out into hardware and created the interpretation software that attracted Tute.

Sanofi explores 'strategic options' for Merial in bid to cut costs

Sanofi's animal health unit, Merial, hasn't been all that synergistic with the company's other pursuits, so it was no surprise when rumors emerged in late September that Sanofi CEO Olivier Brandicourt may be weighing a spinoff. On Friday, Brandicourt confirmed during a presentation at Sanofi's Paris headquarters that the company is reviewing options for Merial, as it turns its attentions toward reviving its faltering diabetes franchise.

AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch

AstraZeneca agreed to buy ZS Pharma and its pending-approval kidney drug, one-upping rival bidder Actelion to get its hands on what it believes is a blockbuster in the making.

Allergan beefs up in aesthetics with implant purchase. Does M&A suitor Pfizer approve?

Big Pharma Allergan announced it is bulking up in aesthetics by purchasing London's Northwood Medical Innovation, maker of the earFold device for the correction of prominent ears, with or without asymmetry, in patients 7 or older. The deal marks the third Allergan device deal in recent months.